サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1178521

筋骨格系（MSK）疾患管理の世界市場 - 業界動向と予測（～2030年）

Global Musculoskeletal (MSK) Disease Management Market - Industry Trends Forecast to 2030
出版日: | 発行: Data Bridge Market Research | ページ情報: 英文 840 Pages | 納期: お問合せ

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
筋骨格系（MSK）疾患管理の世界市場 - 業界動向と予測（～2030年）
出版日: 2022年11月01日
発行: Data Bridge Market Research
ページ情報: 英文 840 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の筋骨格系（MSK）疾患管理の市場規模は、2023年～2030年の予測期間において22.8%のCAGRを記録すると予測されています。

市場の成長に寄与している主な要因としては、筋骨格系（MSK）疾患の診断における技術的進歩や、疾患の認知度向上が挙げられます。

当レポートでは、世界の筋骨格系（MSK）疾患管理市場を調査し、市場の促進要因や抑制要因、機会や課題、セグメント・地域別の市場内訳、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

  • PESTEL分析
  • ポーターのファイブフォース分析
  • 主要な戦略的イニシアチブ
  • 市場におけるデジタルリハビリテーションとデジタル理学療法の新たな動向分析
    • デジタルリハビリテーション
    • デジタル理学療法

第5章 疫学

第6章 世界の筋骨格系（MSK）疾患管理市場：規制

第7章 市場概要

  • 促進要因
  • 抑制要因
  • 機会
  • 課題

第8章 世界の筋骨格系（MSK）疾患管理市場：タイプ別

  • 概要
  • デジタルバイオフィードバックシステム
  • 筋骨格に焦点を当てたデジタルアプリ（MDAS）
    • iOSシステム
    • アンドロイドシステム
    • その他のシステム
  • ソリューション
    • 直接サポート
    • 進行状況の追跡
    • その他
  • その他

第9章 世界の筋骨格系（MSK）疾患管理市場：技術別

  • 概要
  • 精密モーション技術
  • コンピューターモーション技術
  • その他の技術

第10章 世界の筋骨格系（MSK）疾患管理市場：統合タイプ別

  • 概要
  • 電話
  • タブレット
  • コンピューター
  • その他

第11章 世界の筋骨格系（MSK）疾患管理市場：モダリティ別

  • 概要
  • バーチャル療法
  • 対面療法
  • カスタマイズ/パーソナライズされた療法
  • その他

第12章 世界の筋骨格系（MSK）疾患管理市場：用途別

  • 概要
  • 手術前の用途
  • 手術後の用途

第13章 世界の筋骨格系（MSK）疾患管理市場：患者人口別

  • 概要
  • 小児
  • 大人
  • 高齢者

第14章 世界の筋骨格系（MSK）疾患管理市場：エンドユーザー別

  • 概要
  • 病院・クリニック
  • 養護施設
  • 健康センター
  • リハビリセンター
  • バーチャル/在宅医療
  • その他

第15章 世界の筋骨格系（MSK）疾患管理市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • アジア太平洋地域
    • 中国
    • 日本
    • 韓国
    • インド
    • オーストラリア
    • ニュージーランド
    • シンガポール
    • タイ
    • マレーシア
    • ベトナム
    • 台湾
    • インドネシア
    • フィリピン
    • その他アジア太平洋地域
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • トルコ
    • ベルギー
    • デンマーク
    • オランダ
    • スイス
    • スウェーデン
    • ポーランド
    • ノルウェー
    • フィンランド
    • その他欧州
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • バーレーン
    • アラブ首長国連邦
    • クウェート
    • オマーン
    • カタール
    • エジプト
    • イスラエル
    • その他中東・アフリカ
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米

第16章 世界の筋骨格系（MSK）疾患管理市場：企業情勢

  • 企業シェア分析：世界
  • 企業シェア分析：北米
  • 企業シェア分析：欧州
  • 企業シェア分析：アジア太平洋地域

第17章 SWOT分析

第18章 企業プロファイル

  • HINGE HEALTH, INC
  • SWORD HEALTH, INC
  • OMADA HEALTHA INC.
  • KAIA HEALTH
  • WELLNESS COACHES USA, LLC.
  • AIRROSTI REHAB CENTER, LLC
  • DARIOHEALTH CORP. (2021年)
  • INCLUDEHEALTH (2021年)
  • IMC (2021年)
  • KIIO
  • LIMBER HEALTH, INC.
  • MOVEMENT RX (2021年)
  • PHZIO (2021年)
  • RECOVERYONE
  • SPARTA SCIENCE
  • SPRITE HEALTH
  • SIMPLETHERAPY, INC.

第19章 アンケート

第20章 関連レポート

図表

15 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION 279

  • 15.1 OVERVIEW 280
  • 15.2 NORTH AMERICA 286
    • 15.2.1 U.S. 302
    • 15.2.2 CANADA 312
    • 15.2.3 MEXICO 322
  • 15.3 ASIA-PACIFIC 332
    • 15.3.1 CHINA 348
    • 15.3.2 JAPAN 358
    • 15.3.3 SOUTH KOREA 368
    • 15.3.4 INDIA 378
    • 15.3.5 AUSTRALIA 388
    • 15.3.6 NEW ZEALAND 398
    • 15.3.7 SINGAPORE 408
    • 15.3.8 THAILAND 418
    • 15.3.9 MALAYSIA 428
    • 15.3.10 VIETNAM 438
    • 15.3.11 TAIWAN 448
    • 15.3.12 INDONESIA 458
    • 15.3.13 PHILIPPINES 468
    • 15.3.14 REST OF ASIA PACIFIC 478
  • 15.4 EUROPE 479
    • 15.4.1 GERMANY 497
    • 15.4.2 FRANCE 508
    • 15.4.3 U.K. 519
    • 15.4.4 ITALY 530
    • 15.4.5 SPAIN 541
    • 15.4.6 RUSSIA 552
    • 15.4.7 TURKEY 563
    • 15.4.8 BELGIUM 574
    • 15.4.9 DENMARK 585
    • 15.4.10 NETHERLANDS 596
    • 15.4.11 SWITZERLAND 607
    • 15.4.12 SWEDEN 618
    • 15.4.13 POLAND 629
    • 15.4.14 NORWAY 640
    • 15.4.15 FINLAND 651
    • 15.4.16 REST OF EUROPE 662
  • 15.5 MIDDLE EAST AND AFRICA 663
    • 15.5.1 SOUTH AFRICA 679
    • 15.5.2 SAUDI ARABIA 689
    • 15.5.3 BAHRAIN 699
    • 15.5.4 UAE 709
    • 15.5.5 KUWAIT 719
    • 15.5.6 OMAN 729
    • 15.5.7 QATAR 739
    • 15.5.8 EGYPT 749
    • 15.5.9 ISRAEL 759
    • 15.5.10 REST OF MIDDLE EAST AND AFRICA 769
  • 15.6 SOUTH AMERICA 770
    • 15.6.1 BRAZIL 785
    • 15.6.2 ARGENTINA 795
    • 15.6.3 REST OF SOUTH AMERICA 805

16 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY LANDSCAPE 806

  • 16.1 COMPANY SHARE ANALYSIS: GLOBAL 806
  • 16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 807
  • 16.3 COMPANY SHARE ANALYSIS: EUROPE 808
  • 16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 809

17 SWOT ANALYSIS 810

18 COMPANY PROFILE 811

  • 18.1 HINGE HEALTH, INC 811
    • 18.1.1 COMPANY SNAPSHOT 811
    • 18.1.2 COMPANY SHARE ANALYSIS 811
    • 18.1.3 PRODUCT PORTFOLIO 812
    • 18.1.4 RECENT DEVELOPMENTS 812
  • 18.2 SWORD HEALTH, INC 813
    • 18.2.1 COMPANY SNAPSHOT 813
    • 18.2.2 COMPANY SHARE ANALYSIS 813
    • 18.2.3 PRODUCT PORTFOLIO 813
    • 18.2.4 RECENT DEVELOPMENT 814
  • 18.3 OMADA HEALTHA INC. 815
    • 18.3.1 COMPANY SNAPSHOT 815
    • 18.3.2 COMPANY SHARE ANALYSIS 815
    • 18.3.3 PRODUCT PORTFOLIO 815
    • 18.3.4 RECENT DEVELOPMENT 816
  • 18.4 KAIA HEALTH 817
    • 18.4.1 COMPANY SNAPSHOT 817
    • 18.4.2 COMPANY SHARE ANALYSIS 817
    • 18.4.3 PRODUCT PORTFOLIO 817
    • 18.4.4 RECENT DEVELOPMENTS 818
  • 18.5 WELLNESS COACHES USA, LLC. 819
    • 18.5.1 COMPANY SNAPSHOT 819
    • 18.5.2 COMPANY SHARE ANALYSIS 819
    • 18.5.3 PRODUCT PORTFOLIO 819
    • 18.5.4 RECENT DEVELOPMENT 820
  • 18.6 AIRROSTI REHAB CENTER, LLC 821
    • 18.6.1 COMPANY SNAPSHOT 821
    • 18.6.2 PRODUCT PORTFOLIO 821
    • 18.6.3 RECENT DEVELOPMENTS 822
  • 18.7 DARIOHEALTH CORP. (2021) 823
    • 18.7.1 COMPANY SNAPSHOT 823
    • 18.7.2 REVENUE ANALYSIS 823
    • 18.7.3 PRODUCT PORTFOLIO 824
    • 18.7.4 RECENT DEVELOPMENTS 824
  • 18.8 INCLUDEHEALTH (2021) 825
    • 18.8.1 COMPANY SNAPSHOT 825
    • 18.8.2 PRODUCT PORTFOLIO 825
    • 18.8.3 RECENT DEVELOPMENTS 825
  • 18.9 IMC (2021) 826
    • 18.9.1 COMPANY SNAPSHOT 826
    • 18.9.2 PRODUCT PORTFOLIO 826
    • 18.9.3 RECENT DEVELOPMENT 826
  • 18.10 KIIO 827
    • 18.10.1 COMPANY SNAPSHOT 827
    • 18.10.2 PRODUCT PORTFOLIO 827
    • 18.10.3 RECENT DEVELOPMENT 828
  • 18.11 LIMBER HEALTH, INC. 829
    • 18.11.1 COMPANY SNAPSHOT 829
    • 18.11.2 PRODUCT PORTFOLIO 829
    • 18.11.3 RECENT DEVELOPMENT 829
  • 18.12 MOVEMENT RX (2021) 830
    • 18.12.1 COMPANY SNAPSHOT 830
    • 18.12.2 PRODUCT PORTFOLIO 830
    • 18.12.3 RECENT DEVELOPMENT 830
  • 18.13 PHZIO (2021) 831
    • 18.13.1 COMPANY SNAPSHOT 831
    • 18.13.2 PRODUCT PORTFOLIO 831
    • 18.13.3 RECENT DEVELOPMENT 831
  • 18.14 RECOVERYONE 832
    • 18.14.1 COMPANY SNAPSHOT 832
    • 18.14.2 PRODUCT PORTFOLIO 832
    • 18.14.3 RECENT DEVELOPMENT 832
  • 18.15 SPARTA SCIENCE 833
    • 18.15.1 COMPANY SNAPSHOT 833
    • 18.15.2 PRODUCT PORTFOLIO 833
    • 18.15.3 RECENT DEVELOPMENTS 834
  • 18.16 SPRITE HEALTH 835
    • 18.16.1 COMPANY SNAPSHOT 835
    • 18.16.2 PRODUCT PORTFOLIO 835
    • 18.16.3 RECENT DEVELOPMENTS 835
  • 18.17 SIMPLETHERAPY, INC. 836
    • 18.17.1 COMPANY SNAPSHOT 836
    • 18.17.2 PRODUCT PORTFOLIO 836
    • 18.17.3 RECENT DEVELOPMENT 836

19 QUESTIONNAIRE 837

20 RELATED REPORTS 840

LIST OF FIGURES

  • FIGURE 1 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SEGMENTATION 105
  • FIGURE 2 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: GEOGRAPHIC SCOPE 106
  • FIGURE 3 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DATA TRIANGULATION 108
  • FIGURE 4 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT 109
  • FIGURE 5 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BOTTOM-UP APPROACH 110
  • FIGURE 6 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: TOP-DOWN APPROACH 110
  • FIGURE 7 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: INTERVIEWS BY REGION AND DESIGNATION 111
  • FIGURE 8 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DBMR MARKET POSITION GRID 113
  • FIGURE 9 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: VENDOR SHARE ANALYSIS 115
  • FIGURE 10 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: APPLICATION COVERAGE GRID 116
  • FIGURE 11 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: THE CATEGORY VS TIME GRID 117
  • FIGURE 12 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET SEGMENTATION 121
  • FIGURE 13 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 122
  • FIGURE 14 RISE IN AWARENESS ABOUT MUSCULOSKELETAL (MSK) DISEASES, GROWING PREVALENCE OF RHEUMATOID ARTHRITIS, TECHNOLOGICAL ADVANCEMENTS IN MUSCULOSKELETAL (MSK) DISEASES, AND STRATEGIC INITIATIVES BY MARKET PLAYERS ARE EXPECTED TO DRIVE THE MARKET GROWTH FOR GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 123
  • FIGURE 15 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN 2023 & 2030 123
  • FIGURE 16 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE INCREASING WITH A STRONG CAGR IN THE FORECAST PERIOD FROM 2023 TO 2030 124
  • FIGURE 17 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET : EPIDEMIOLOGY 173
  • FIGURE 18 PREVALENCE AND INCIDENCE OF RHEUMATOID ARTHRITIS 174
  • FIGURE 19 PREVALENCE AND INCIDENCE OF OSTEOARTHRITIS 175
  • FIGURE 20 PREVALENCE AND INCIDENCE OF OSTEOPOROSIS 176
  • FIGURE 21 PREVALENCE AND INCIDENCE OF PSORIATIC ARTHRITIS 177
  • FIGURE 22 PREVALENCE AND INCIDENCE OF ANKYLOSING SPONDYLITIS 178
  • FIGURE 23 INCIDENSE OF FIBROMYALGIA 179
  • FIGURE 24 PREVALENCE AND INCIDENCE OF TENDINITIS AND CARPEL TUNNEL SYNDROME 180
  • FIGURE 25 PREVALENCE AND INCIDENCE OF BONE FRACTURES 181
  • FIGURE 26 PREVALENCE AND INCIDENCE OF OSTEOMALACIA AND OSTEOPENIA 182
  • FIGURE 27 PREVALENCE AND INCIDENCE OF GOUT 183
  • FIGURE 28 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET 192
  • FIGURE 29 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2022 203
  • FIGURE 30 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2023-2030 (USD MILLION) 204
  • FIGURE 31 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, CAGR (2023-2030) 204
  • FIGURE 32 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, LIFELINE CURVE 205
  • FIGURE 33 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2022 216
  • FIGURE 34 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 217
  • FIGURE 35 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, CAGR (2023-2030) 217
  • FIGURE 36 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, LIFELINE CURVE 218
  • FIGURE 37 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2022 223
  • FIGURE 38 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2023-2030 (USD MILLION) 224
  • FIGURE 39 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, CAGR (2023-2030) 224
  • FIGURE 40 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, LIFELINE CURVE 225
  • FIGURE 41 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2022 234
  • FIGURE 42 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2023-2030 (USD MILLION) 235
  • FIGURE 43 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, CAGR (2023-2030) 235
  • FIGURE 44 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, LIFELINE CURVE 236
  • FIGURE 45 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2022 245
  • FIGURE 46 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 246
  • FIGURE 47 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, CAGR (2023-2030) 246
  • FIGURE 48 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, LIFELINE CURVE 247
  • FIGURE 49 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2022 259
  • FIGURE 50 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2023-2030 (USD MILLION) 260
  • FIGURE 51 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, CAGR (2023-2030) 260
  • FIGURE 52 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, LIFELINE CURVE 261
  • FIGURE 53 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2022 266
  • FIGURE 54 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2023-2030 (USD MILLION) 267
  • FIGURE 55 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, CAGR (2023-2030) 267
  • FIGURE 56 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, LIFELINE CURVE 268
  • FIGURE 57 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT (2022) 281
  • FIGURE 58 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY REGION (2022) 283
  • FIGURE 59 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY REGION (2023 & 2030) 283
  • FIGURE 60 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY REGION (2022 & 2030) 284
  • FIGURE 61 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE (2023-2030) 284
  • FIGURE 62 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT (2022) 287
  • FIGURE 63 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022) 289
  • FIGURE 64 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2023 & 2030) 289
  • FIGURE 65 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022 & 2030) 290
  • FIGURE 66 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE (2023-2030) 290
  • FIGURE 67 ASIA-PACIFIC MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT (2022) 333
  • FIGURE 68 ASIA-PACIFIC MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022) 335
  • FIGURE 69 ASIA-PACIFIC MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2023 & 2030) 335
  • FIGURE 70 ASIA-PACIFIC MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022 & 2030) 336
  • FIGURE 71 ASIA-PACIFIC MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE (2023-2030) 336
  • FIGURE 72 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT (2022) 480
  • FIGURE 73 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022) 482
  • FIGURE 74 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2023 & 2030) 482
  • FIGURE 75 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022 & 2030) 483
  • FIGURE 76 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE (2023-2030) 484
  • FIGURE 77 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT (2022) 664
  • FIGURE 78 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022) 666
  • FIGURE 79 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2023 & 2030) 666
  • FIGURE 80 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022 & 2030) 667
  • FIGURE 81 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE (2023-2030) 667
  • FIGURE 82 SOUTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT (2022) 771
  • FIGURE 83 SOUTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022) 773
  • FIGURE 84 SOUTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2023 & 2030) 773
  • FIGURE 85 SOUTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022 & 2030) 774
  • FIGURE 86 SOUTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE (2023-2030) 774
  • FIGURE 87 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY SHARE 2022 (%) 806
  • FIGURE 88 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY SHARE 2022 (%) 807
  • FIGURE 89 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY SHARE 2022 (%) 808
  • FIGURE 90 ASIA-PACIFIC MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY SHARE 2022 (%) 809
目次

Global musculoskeletal (MSK) disease management market is projected to register a CAGR of 22.8% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation

Global Musculoskeletal (MSK) Disease Management Market, By Type (Digital Biofeedback System, Musculoskeletal-focused Digital Apps (MDAs), Solutions, and Others), Technology (Precision Motion Technology, Computer Vision Technology, and Other Technologies), Integration Type (Phone, Tablet, Computer, and Others), Modality (Virtual Therapy, In-Person Therapy, Customized/Personalized Therapy, and Others), Application (Pre-Surgery Applications and Post-Surgery Applications), Patient Population (Pediatrics, Adults, and Geriatrics), End User (Hospitals & Clinics, Nursing Homes, Health Centers, Rehabilitation Centres, Virtual/Home Health Care Settings, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Sweden, Poland, Norway, Finland, Rest of Europe, China, Japan, India, South Korea, Singapore, Thailand, Vietnam, Taiwan, Malaysia, Australia, Philippines, Indonesia, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Bahrain, Kuwait, Oman, Katar, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the global musculoskeletal (MSK) disease management market are:

Technological advances in the diagnosis of Musculoskeletal (MSK) diseases

Rising awareness about Musculoskeletal (MSK) diseases

Market Players

The key market players operating in the global musculoskeletal (MSK) disease management market are listed below:

Sword Health, Inc.

DarioHealth Corp.

IncludeHealth

Wellness Coaches USA, LLC

SimpleTherapy, Inc.

Hinge Health, Inc.

SPRITE HEALTH

Limber Health, Inc.

kaia health

RecoveryOne

Kiio

Omada Health Inc.

IMC.

Sparta Science

Movement RX

Phzio.

Airrosti Rehab Center, LLC

TABLE OF CONTENTS

1 INTRODUCTION 94

  • 1.1 OBJECTIVES OF THE STUDY 94
  • 1.2 MARKET DEFINITION 94
  • 1.3 OVERVIEW OF THE GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET 94
  • 1.4 CURRENCY AND PRICING 97
  • 1.5 LIMITATION 97
  • 1.6 MARKETS COVERED 98

2 MARKET SEGMENTATION 105

  • 2.1 MARKETS COVERED 105
  • 2.2 GEOGRAPHIC SCOPE 106
  • 2.3 YEARS CONSIDERED FOR THE STUDY 107
  • 2.4 CURRENCY AND PRICING 107
  • 2.5 RESEARCH METHODOLOGY 108
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 111
  • 2.7 MULTIVARIATE MODELLING 112
  • 2.8 TYPE SEGMENT LIFELINE CURVE 112
  • 2.9 DBMR MARKET POSITION GRID 113
  • 2.10 VENDOR SHARE ANALYSIS 115
  • 2.11 MARKET APPLICATION COVERAGE GRID 116
  • 2.12 THE CATEGORY VS TIME GRID 117
  • 2.13 SECONDARY SOURCES 118
  • 2.14 ASSUMPTIONS 118

3 EXECUTIVE SUMMARY 119

4 PREMIUM INSIGHTS 123

  • 4.1 PESTEL ANALYSIS 125
  • 4.2 PORTER'S FIVE FORCE 126
  • 4.3 KEY STRATEGIC INITIATIVES 127
  • 4.4 EMERGING TREND ANALYSIS OF DIGITAL REHABILITATION AND DIGITAL PHYSIOTHERAPY IN THE GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET 129
    • 4.4.1 DIGITAL REHABILITATION 129
    • 4.4.2 DIGITAL PHYSIOTHERAPY 129

5 EPIDEMOLOGY 131

  • 5.1 US 132
  • 5.2 CANADA 133
  • 5.3 MEXICO 133
  • 5.4 GERMANY 134
  • 5.5 FRANCE 135
  • 5.6 U.K. 136
  • 5.7 ITALY 137
  • 5.8 SPAIN 138
  • 5.9 RUSSIA 139
  • 5.10 TURKEY 140
  • 5.11 BELGIUM 141
  • 5.12 DENMARK 142
  • 5.13 NETHERLANDS 143
  • 5.14 SWITZERLAND 144
  • 5.15 SWEDEN 145
  • 5.16 POLAND 146
  • 5.17 NORWAY 147
  • 5.18 FINLAND 148
  • 5.19 CHINA 149
  • 5.20 JAPAN 150
  • 5.21 SOUTH KOREA 151
  • 5.22 INDIA 152
  • 5.23 AUSTRALIA 153
  • 5.24 NEW ZEALAND 154
  • 5.25 SINGAPORE 155
  • 5.26 THAILAND 156
  • 5.27 MALAYSIA 157
  • 5.28 VIETNAM 158
  • 5.29 TAIWAN 159
  • 5.30 INDONESIA 160
  • 5.31 PHILIPPINES 161
  • 5.32 BRAZIL 162
  • 5.33 ARGENTINA 163
  • 5.34 SOUTH AFRICA 164
  • 5.35 SAUDI ARABIA 165
  • 5.36 BAHRAIN 166
  • 5.37 U.A.E 167
  • 5.38 KUWAIT 168
  • 5.39 OMAN 169
  • 5.40 QATAR 170
  • 5.41 EGYPT 171
  • 5.42 ISRAEL 172

6 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: REGULATIONS 184

7 MARKET OVERVIEW 191

  • 7.1 DRIVERS 193
    • 7.1.1 TECHNOLOGICAL ADVANCES IN THE DIAGNOSIS OF MUSCULOSKELETAL DISORDERS (MSDS) 193
    • 7.1.2 RISING AWARENESS ABOUT MUSCULOSKELETAL DISORDERS (MSDS) 193
    • 7.1.3 GROWING PREVALENCE OF RHEUMATOID ARTHRITIS (RA) 194
    • 7.1.4 INCREASING CASES OF BONE FRACTURES 194
  • 7.2 RESTRAINTS 195
    • 7.2.1 HIGH COST OF DIAGNOSIS AND TREATMENT OF ORTHOPEDIC DISEASES 195
    • 7.2.2 RISE IN USE OF HEAVY-DUTY DRUGS IN TREATING MUSCULOSKELETAL (MSK) PAIN 196
  • 7.3 OPPORTUNITIES 196
    • 7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 196
    • 7.3.2 USE OF TELEMEDICINE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT 197
    • 7.3.3 INCREASED USE OF MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT 198
    • 7.3.4 USE OF HOME HEALTHCARE FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT 198
  • 7.4 CHALLENGES 199
    • 7.4.1 CHALLENGES FACED BY PHYSICIANS WHILE TREATING ATHLETES WITH MUSCULOSKELETAL (MSK) DISEASES 199
    • 7.4.2 STRICT REGULATORY GUIDELINES FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT 199

8 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE 201

  • 8.1 OVERVIEW 202
  • 8.2 DIGITAL BIOFEEDBACK SYSTEM 206
  • 8.3 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) 207
    • 8.3.1 IOS-SYSTEMS 208
    • 8.3.2 ANDROID-SYSTEMS 208
    • 8.3.3 OTHER SYSTEMS 208
  • 8.4 SOLUTIONS 208
    • 8.4.1 DIRECT SUPPORT 210
      • 8.4.1.1 MULTIMODAL PAIN THERAPY 211
      • 8.4.1.2 ONSITE PERSONALIZED THERAPY 211
      • 8.4.1.3 SOLUTIONS TO REDUCE INJURIES 211
      • 8.4.1.4 MIND-BODY CONNECTION IMPROVEMENT 211
      • 8.4.1.5 EARLY PREVENTION AND INTERVENTION 211
      • 8.4.1.6 PREVENTION, RECOVERY AND EDUCATION 211
      • 8.4.1.7 PERSONALIZED PAIN RECOVERY 211
      • 8.4.1.8 SENSOR-GUIDED EXERCISE THERAPY 211
      • 8.4.1.9 TRAINING OF EDUCATION SKILLS 211
      • 8.4.1.10 SELF-TRACKING OF PAIN EPISODES 211
      • 8.4.1.11 RELAXATION TECHNIQUES 212
      • 8.4.1.12 POST-OPERATIVE PAIN TRACKING 212
        • 8.4.1.12.1 REAL-TIME MONITORING 212
        • 8.4.1.12.2 SYMPTOM MANAGEMENT 212
      • 8.4.1.13 OTHERS 212
    • 8.4.2 PROGRESS TRACKING 212
    • 8.4.3 OTHERS 212
  • 8.5 OTHERS 213

9 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY 214

  • 9.1 OVERVIEW 215
  • 9.2 PRECISION MOTION TECHNOLOGY 219
  • 9.3 COMPUTER MOTION TECHNOLOGY 219
  • 9.4 OTHER TECHNOLOGIES 220

10 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE 221

  • 10.1 OVERVIEW 222
  • 10.2 PHONE 226
    • 10.2.1 DIGITAL BIOFEEDBACK SYSTEM 227
    • 10.2.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) 227
    • 10.2.3 THERAPIES 227
    • 10.2.4 OTHERS 227
  • 10.3 TABLET 227
    • 10.3.1 DIGITAL BIOFEEDBACK SYSTEM 229
    • 10.3.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) 229
    • 10.3.3 THERAPIES 229
    • 10.3.4 OTHERS 229
  • 10.4 COMPUTER 229
    • 10.4.1 DIGITAL BIOFEEDBACK SYSTEM 230
    • 10.4.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) 230
    • 10.4.3 THERAPIES 230
    • 10.4.4 OTHERS 230
  • 10.5 OTHERS 231

11 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY 232

  • 11.1 OVERVIEW 233
  • 11.2 VIRTUAL THERAPY 237
    • 11.2.1 INTERNET BASED 238
    • 11.2.2 TELEPHONE BASED 239
    • 11.2.3 MOBILE PHONE APPLICATION 239
    • 11.2.4 INTERNET BASED WITH TELEPHONE SUPPORT 239
    • 11.2.5 INTERACTIVE VOICE RESPONSE 239
    • 11.2.6 VIDEO TELECONFERENCING 239
    • 11.2.7 MOBILE PHONE APPLICATION WITH TELEPHONE SUPPORT 239
    • 11.2.8 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT 239
    • 11.2.9 INTERNET BASED WITH VIDEO CONFERENCING 239
    • 11.2.10 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT AND INTERNET BASED 239
    • 11.2.11 OTHERS 240
  • 11.3 IN-PERSON THERAPY 240
  • 11.4 CUSTOMIZED/ PERSONALIZED THERAPY 241
  • 11.5 OTHERS 242

12 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION 243

  • 12.1 OVERVIEW 244
  • 12.2 PRE-SURGERY APPLICATION 248
    • 12.2.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY 249
    • 12.2.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY 249
    • 12.2.3 LATERAL LUMBAR INTERBODY FUSION SURGERY 249
    • 12.2.4 INTERNET BASED WITH TELEPHONE SUPPORT 249
    • 12.2.5 MINIMALLY INVASIVE SPINE SURGERY 250
    • 12.2.6 MOTION PRESERVING SPINE SURGERY 250
    • 12.2.7 POSTERIOR CERVICAL FUSION SURGERY 250
    • 12.2.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY 250
    • 12.2.9 SACROILIAC JOINT FUSION SURGERY 250
    • 12.2.10 SCOLIOSIS CORRECTION SURGERY 250
    • 12.2.11 VERTEBRAL AUGMENTATION SURGERY 250
    • 12.2.12 FRACTURE FIXATION SURGERY 250
    • 12.2.13 HIP SURGERY 250
      • 12.2.13.1 TOTAL HIP REPLACEMENT 251
      • 12.2.13.2 PARTIAL HIP REPLACEMENT 251
      • 12.2.13.3 HIP RESURFACING 251
      • 12.2.13.4 OTHERS 251
    • 12.2.14 KNEE SURGERY 251
      • 12.2.14.1 TOTAL KNEE REPLACEMENT 252
      • 12.2.14.2 PARTIAL KNEE REPLACEMENT 252
      • 12.2.14.3 MISS FUSION 252
      • 12.2.14.4 OTHERS 252
  • 12.3 POST-SURGERY APPLICATION 252
    • 12.3.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY 254
    • 12.3.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY 254
    • 12.3.3 LATERAL LUMBAR INTERBODY FUSION SURGERY 254
    • 12.3.4 INTERNET BASED WITH TELEPHONE SUPPORT 254
    • 12.3.5 MINIMALLY INVASIVE SPINE SURGERY 254
    • 12.3.6 MOTION PRESERVING SPINE SURGERY 254
    • 12.3.7 POSTERIOR CERVICAL FUSION SURGERY 254
    • 12.3.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY 254
    • 12.3.9 SACROILIAC JOINT FUSION SURGERY 254
    • 12.3.10 SCOLIOSIS CORRECTION SURGERY 254
    • 12.3.11 VERTEBRAL AUGMENTATION SURGERY 255
    • 12.3.12 FRACTURE FIXATION SURGERY 255
    • 12.3.13 HIP SURGERY 255
      • 12.3.13.1 TOTAL HIP REPLACEMENT 255
      • 12.3.13.2 PARTIAL HIP REPLACEMENT 255
      • 12.3.13.3 HIP RESURFACING 255
      • 12.3.13.4 OTHERS 256
    • 12.3.14 KNEE SURGERY 256
      • 12.3.14.1 TOTAL KNEE REPLACEMENT 256
      • 12.3.14.2 PARTIAL KNEE REPLACEMENT 256
      • 12.3.14.3 MISS FUSION 256
      • 12.3.14.4 OTHERS 256

13 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION 257

  • 13.1 OVERVIEW 258
  • 13.2 PEDIATRICS 262
    • 13.2.1 MALE 262
    • 13.2.2 FEMALE 262
  • 13.3 ADULTS 263
    • 13.3.1 MALE 263
    • 13.3.2 FEMALE 263
  • 13.4 GERIATRIC 264
    • 13.4.1 MALE 264
    • 13.4.2 FEMALE 264

14 GLOBAL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER 265

  • 14.1 OVERVIEW 266
  • 14.2 HOSPITALS & CLINICS 269
    • 14.2.1 MULTIPLE 270
    • 14.2.2 PHYSICAL THERAPIST 270
    • 14.2.3 NURSE 270
    • 14.2.4 HEALTH COACH 270
    • 14.2.5 OTHERS 270
  • 14.3 NURSING HOMES 270
    • 14.3.1 MULTIPLE 272
    • 14.3.2 PHYSICAL THERAPIST 272
    • 14.3.3 NURSE 272
    • 14.3.4 HEALTH COACH 272
    • 14.3.5 OTHERS 272
  • 14.4 HEALTH CENTERS 272
    • 14.4.1 MULTIPLE 273
    • 14.4.2 PHYSICAL THERAPIST 273
    • 14.4.3 NURSE 273
    • 14.4.4 HEALTH COACH 274
    • 14.4.5 OTHERS 274
  • 14.5 REHABILITATION CENTERS 274
    • 14.5.1 MULTIPLE 275
    • 14.5.2 PHYSICAL THERAPIST 275
    • 14.5.3 NURSE 275
    • 14.5.4 HEALTH COACH 275
    • 14.5.5 OTHERS 275
  • 14.6 VIRTUAL/HOME HEALTH CARE SETTINGS 275
    • 14.6.1 MULTIPLE 277
    • 14.6.2 PHYSICAL THERAPIST 277
    • 14.6.3 NURSE 277
    • 14.6.4 HEALTH COACH 277
    • 14.6.5 OTHERS 277
  • 14.7 OTHERS 277